Shots:

• Gilead to acquire MYR for ~$1.4B in the all-cash transaction along with ~$364.73M as a milestone upon the US FDA’s approval of Hepcludex (bulevirtide)
• The acquisition will provide Gilead with Hepcludex which has received EMA’s conditional approval for chronic HDV infection in adults with compensated liver disease in Jul’2020. MYR anticipates the submission for accelerated approval to the US FDA based on P-II MYR203 study in H2’21
• Hepcludex (SC) blocks the NTCP receptor on the surface of hepatocytes & prevents the entry of HBV/HDV into hepatocytes & viral spread within the liver and has received the US FDA’s & EMA’s ODD for HDV

 ­ Ref: Gilead | Image: New Indian Express